⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 2, 2024Open Access

Figure S5. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models

View Full Paper

Ask AI

Bookmark

Share

Abstract

Antitumor activity of CB-011 CAR-T cells in a xenograft model of multiple myeloma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Degagné et al. (2024) studied this question.

synapsesocial.com/papers/68e70c5ab6db6435876860b6 https://doi.org/10.1158/2326-6066.25523531.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S6. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models2024
2Figure S3. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models2024
3Figure S2. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models2024
4Figure S7. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models2024
5Figure S4. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models2024